Comparison
BPC-157 vs. Cagrilintide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Metabolic
CAS no.
137525-51-0
1415456-99-3
Molecular weight
1419.5 g/mol
4253.7 g/mol
Half-life
4 h
168 h
Sequence
GEPPPGKPADDAGLVKCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
4
of which in humans
0
3
Effects recorded
4
3
Open conflicts
2
0
Documented adverse events
2
1